# Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer

> **NCT00002953** · PHASE3 · COMPLETED · sponsor: **Medical Research Council** · enrollment: 704 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** epirubicin hydrochloride
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00002953
- **Lead sponsor:** Medical Research Council
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-12
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 704 (ESTIMATED)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002953, "Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00002953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*